RPHM 0.00 Reneo Pharmaceuticals, Inc.
| Range: | 1.68-86.7 | Vol Avg: | 17796 | Last Div: | 0 | Changes: | 16.47 |
| Beta: | 0.22 | Cap: | 0.06B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Apr 08 2021 | Empoloyees: | 8 | ||
| CUSIP: | 75974E103 | CIK: | 0001637715 | ISIN: | US75974E1038 | Country: | US |
| CEO: | Mr. Gregory J. Flesher | Website: | https://reneopharma.com | ||||
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Stock Details
Neutral 0.00
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 rever...
globenewswire.com·Thu Oct 03 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow